A.V. Sultanbaev1, A.A. Izmaylov1, O.N. Lipatov2, A.F. Nasretdinov1, K.V. Menshikov1,2, N.I. Sultanbayeva1, Sh.I. Musin1, G.A. Serebrennikov2
1Republican Clinical Oncology Dispensary, Ufa
2Bashkir State Medical University, Ufa
Sultanbaev Aleksandr V. ― Cand. of Sci. (Med.), Head of the Department of antitumor drug Therapy of the Republican Clinical Oncology Dispensary
73/1 Oktyabrya Ave., Ufa, 450054, Russian Federation, e-mail: email@example.com, ORCID ID: 0000-0003-0996-5995
Abstract. The article presents a regional real clinical experience with the use of durvalumab in patients with unresectable non-small cell lung cancer after radical chemoradiotherapy. The obtained statistical data on the antitumor activity of the drug are comparable with the results of clinical studies, which confirms the effectiveness of this therapy in real clinical practice.
A total of 44 patients treated with durvalumab after chemoradiotherapy (CRT) were studied. Of the 44 patients, 39 completed a six-month follow-up without signs of progression, 8 completed a year of therapy with a mean progression-free follow-up of 14,6 months. There were 5 cases of progression during durvalumab therapy. In total, 2 cases of adverse events of 3-4 degrees of toxicity were registered, which led to the cancel of therapy.
Key words: NSCLC, lung cancer, durvalumab, chemoradiotherapy.